The National Institute of Health and Care Excellence (NICE) – the drugs advisory body to the National Health Service (NHS) in the UK – has criticized Roche Holding Ltd. (ADR) (RHHBY) over its refusal to cut prices for Kadcyla, which is used to treat severe cases of breast cancer. Kadcyla is approved to treat HER2-positive…
Novartis AG (ADR) (NYSE:NVS) announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal disease caused by serogroup B (meningitis B) in adolescents and young adults…
Synageva BioPharma Corp (NASDAQ:GEVA) last released its earnings data on Friday, May 2nd. The company reported ($1.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($1.19) by $0.03. Analysts expect that Synageva BioPharma Corp will post $-5.90 EPS for the current fiscal year. Synageva BioPharma Corp (NASDAQ:GEVA)stock performance was 5.87% in…
